Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Tumor's DNA guide better cancer care for kids?

NCT ID NCT05691608

Knowledge-focused Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Sep 15, 2026 · Updated 3 times

Summary

This study looks at whether analyzing the genetic makeup of tumors from children and young adults with cancer that has returned or not responded to treatment can help doctors choose more personalized therapies. Participants provide tumor and blood samples, which are sequenced to find specific genetic changes. A team of experts then discusses these results to recommend targeted treatment options. The goal is to improve survival and introduce new treatment strategies for advanced pediatric cancers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tumor biopsy and blood sample for molecular profiling
What this could lead to
If successful, this could help match more children with advanced cancer to targeted treatments based on their tumor's unique genetic makeup, potentially improving outcomes.
What could go wrong
This is an observational profiling study, not a treatment trial, so it may not directly benefit participants. The success depends on whether identified genetic changes can be matched to available drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 25 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient referred for sequencing of the tumor within the FMG2025 or equivalent program and written consent for FMG2025 - Cancers et leucémies pédiatriques en échec de traitement or equivalent signed * Written informed consent for MAPPYACTS 2 (or non-opposition for retrospective clinical data collection) according to local or national regulations * Patient with confirmed solid tumor or leukemia which is relapsed or refractory to standard treatment and who is potentially eligible for an experimental treatment or an early phase clinical trial at the time of tumor sequencing * Planned tumor biopsy, surgical resection, bone marrow or blood sample or recently (possibly within the last 3 months) archived frozen tumor material available of the current recurrent or refractory disease * Patients aged ≤ 25 years at the time of initial diagnosis * Performance status and life expectancy \> 3 months at the time of tumor sequencing that allows enrolment into an experimental trial * Patients affiliated with a Social Security Regimen or beneficiary of the same as per local regulatory requirements Exclusion Criteria: * Any concurrent illness or laboratory abnormality that, in the opinion of the investigator, is likely to interfere with the interpretation of study results * Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leukemia Solid tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    29 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU Morvan

    RECRUITING

    Brest, 29200, France

  • CHRU Nancy Hôpital Enfants

    RECRUITING

    Vandœuvre-lès-Nancy, 54500, France

  • CHU Amiens-Picardie

    RECRUITING

    Amiens, France, 80054, France

  • CHU Angers

    RECRUITING

    Angers, 49933 Cedex 9, France

  • CHU Arnaud de Villeneuve

    RECRUITING

    Montpellier, 34295, France

  • CHU Besançon

    RECRUITING

    Besançon, 25030, France

  • CHU Dijon François Mitterand

    RECRUITING

    Dijon, 21079, France

  • CHU Estaing

    RECRUITING

    Clermont-Ferrand, 63000, France

  • CHU Grenoble Alpes

    RECRUITING

    Grenoble, 38043, France

  • CHU La Timone

    RECRUITING

    Marseille, 13005, France

  • CHU Nantes

    RECRUITING

    Nantes, 44093, France

  • CHU Pellegrin

    RECRUITING

    Bordeaux, 33076, France

  • CHU Poitiers

    RECRUITING

    Poitiers, 86022 Cedex, France

  • CHU Reims- Hôpital Américain

    RECRUITING

    Reims, 51100, France

  • CHU Rennes Hôpital Sud

    RECRUITING

    Rennes, 35203, France

  • CHU Saint Etienne

    RECRUITING

    Saint-Etienne, France, 42270, France

  • CHU de Caen

    RECRUITING

    Caen, 14000, France

  • CHU de La Réunion site nord

    RECRUITING

    Saint-Denis, 97400, France

  • CHU de Nice

    RECRUITING

    Nice, 06202, France

  • CHU de Rouen

    RECRUITING

    Rouen, 76000, France

  • Centre Oscar Lambret

    RECRUITING

    Lille, 59020, France

  • Chu Limoges

    RECRUITING

    Limoges, 87000, France

  • Gustave Roussy

    RECRUITING

    Paris, Villejuif, 94800, France

  • Hopital Armand Trousseau

    RECRUITING

    Paris, France, 75012, France

  • Hôpital Clocheville

    RECRUITING

    Tours, 37000, France

  • Hôpital de Hautepierre

    RECRUITING

    Strasbourg, 67200, France

  • Hôpital des Enfants - CHU de Toulouse

    RECRUITING

    Toulouse, 31059, France

  • IHOP

    RECRUITING

    Lyon, 69373, France

  • Institut Curie

    RECRUITING

    Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.